产前游离DNA筛查检测数量:2022年美国病理学家学会能力验证项目结果
2022年12月,美国病理学家学会向22个国家93名参与者发放无创产前检测能力验证项目,74份结果合格。最常见的平台为Illumina/Nextseq(55%),方法为全基因组测序(76%)。
要点
- 最常见平台为Illumina/Nextseq(55%),全基因组测序方法占76%。
- 63家(86%)为营利性机构,18家(25%)提供相关学术培训。
研究设计与样本
- 美国病理学家学会2022-B无创产前检测能力验证项目于2022年12月发放给22个国家的93名参与者。
- 83名来自三大洲的参与者返回结果,其中74名(89%)适合分析。
主要发现
- 鉴定出9种制造商/平台组合,最常见为Illumina/Nextseq(55%)。
- 最常见方法为全基因组测序(76%)。
- 73名受访者中63名(86%)为营利性,8名(11%)为非营利学术或政府支持,其余2名包括医院附属和私立非营利。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Determine current analytical methods and number of cell-free (cf) DNA prenatal screening tests performed for common trisomies. METHODS: The College of American Pathologists 2022-B Noninvasive Prenatal Testing exercise was distributed in December 2022 to 93 participants in 22 countries. Supplemental questions included the number of tests performed in a recent month and the proportion of samples originating outside the United States (US). RESULTS: Eighty-three participants from three continents returned results; 74 (89%) were suitable for the analyses. Nine manufacturer/platform combinations were identified, most commonly Illumina/Nextseq (55%). The most common methodology was whole genome sequencing (76%). Annualized cfDNA tests were 2.80 million, with Asian, European and North American participants representing 10.6%, 6.5% and 82.9% of tests, respectively. When restricted to US in-country tests, the annualized rate was 2.18 million, with four of 20 participants testing 79.2%. Among 73 respondents, 63 (86%) were for-profit, eight (11%) were non-profit academic or government supported and the remaining two included hospital-based and private non-profit. Eighteen (25%) supported relevant academic training. CONCLUSION: In 2011, screening for common trisomies was based on serum/ultrasound markers with an estimated 2.96 million US pregnancies screened in 131 laboratories. In 2022, cfDNA-based screening was offered by 20 laboratories testing 2.18 million US pregnancies.
引用
- Palomaki GE, Wyatt P, Rowsey R, et al. Numbers of prenatal cell-free DNA screens performed: Results of a 2022 CAP exercise. Prenat Diagn. 2024. PMID: 38622635. doi:10.1002/pd.6574
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。